Ishikawa D - Search Results

1

[A case of thymic cancer effectively treated by weekly paclitaxel combined with carboplatin].

Kondo R, Watanabe S, Ishikawa D, Tanaka T, Ohshima Y, Asakawa K, Sakagami T, Okajima M, Miura S, Hayashi Y, Tanaka J, Kagamu H, Yoshizawa H, Narita I. Kondo R, et al. Among authors: ishikawa d. Gan To Kagaku Ryoho. 2014 Dec;41(13):2607-9. Gan To Kagaku Ryoho. 2014. PMID: 25596057 Japanese.

2

Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.

Sato K, Watanabe S, Ohtsubo A, Shoji S, Ishikawa D, Tanaka T, Nozaki K, Kondo R, Okajima M, Miura S, Tanaka J, Sakagami T, Koya T, Kagamu H, Yoshizawa H, Narita I. Sato K, et al. Among authors: ishikawa d. BMC Cancer. 2016 Mar 15;16:222. doi: 10.1186/s12885-016-2271-8. BMC Cancer. 2016. PMID: 26979596 Free PMC article.

3

Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.

Saida Y, Watanabe S, Tanaka T, Baba J, Sato K, Shoji S, Igarashi N, Kondo R, Okajima M, Koshio J, Ichikawa K, Nozaki K, Ishikawa D, Koya T, Miura S, Tanaka J, Kagamu H, Yoshizawa H, Nakata K, Narita I. Saida Y, et al. Among authors: ishikawa d. J Immunol. 2015 Jul 15;195(2):726-35. doi: 10.4049/jimmunol.1401468. Epub 2015 Jun 3. J Immunol. 2015. PMID: 26041539

4

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.

Koyama K, Miura S, Watanabe S, Shoji S, Koshio J, Hayashi Y, Ishikawa D, Sato K, Miyabayashi T, Okajima M, Ota T, Tanaka T, Matsumoto N, Kuriyama H, Abe T, Nozaki K, Ichikawa K, Kondo R, Tanaka H, Kikuchi T. Koyama K, et al. Among authors: ishikawa d. Sci Rep. 2022 Apr 16;12(1):6367. doi: 10.1038/s41598-022-10288-8. Sci Rep. 2022. PMID: 35430596 Free PMC article.

5

[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].

Yamashita K, Ishikawa D, Nanjo S, Takeuchi S, Yamada T, Mouri H, Ohtsubo K, Yasumoto K, Kumagai M, Ueda Y, Yano S. Yamashita K, et al. Among authors: ishikawa d. Gan To Kagaku Ryoho. 2012 Sep;39(9):1427-30. Gan To Kagaku Ryoho. 2012. PMID: 22996784 Japanese.

6

[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective].

Yamada T, Ohtsubo K, Ishikawa D, Nanjo S, Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Yano S. Yamada T, et al. Among authors: ishikawa d. Gan To Kagaku Ryoho. 2012 Aug;39(8):1291-4. Gan To Kagaku Ryoho. 2012. PMID: 22902462 Japanese.

7

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. Ishikawa D, et al. PLoS One. 2013 May 14;8(5):e62104. doi: 10.1371/journal.pone.0062104. Print 2013. PLoS One. 2013. PMID: 23690929 Free PMC article.

8

[Prolonged disturbance of consciousness and respiratory depression induced by controlled-release morphine, requiring long-term naloxone administration in a hemodialysis patient with cancer--a case report].

Izumi N, Okuyama S, Abe K, Ishikawa D, Suzuki S. Izumi N, et al. Among authors: ishikawa d. Gan To Kagaku Ryoho. 2012 Aug;39(8):1295-9. Gan To Kagaku Ryoho. 2012. PMID: 22902463 Review. Japanese.

9

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Nakagawa T, et al. Among authors: ishikawa d. Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25. Mol Cancer Ther. 2012. PMID: 22844075

10

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S. Sano T, et al. Among authors: ishikawa d. Int J Cancer. 2013 Jul 15;133(2):505-13. doi: 10.1002/ijc.28034. Epub 2013 Feb 12. Int J Cancer. 2013. PMID: 23319394

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

264 results

Search Page

Filters